Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without pevonedistat for impending relapse in MDS/AML
2019-004536-37Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Azacitidine monotherapy with Azacitidine + pevonedistat combination (2 arms). Primary endpoint: MRD negativity rate at 3 cycles. Started Jun 2020; status: completed.
02
Drugs
pevonedistatazacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2019-004536-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004536-37.